ALS Treatment: What to Do When Riluzole Adverse Events Persist

In amyotrophic lateral sclerosis (ALS), treatment tolerability requires ongoing reassessment. When a patient continues to experience adverse events from riluzole that do not resolve, a specific clinical decision point is reached that calls for a structured management response.

This protocol addresses ALS patients in whom adverse events related to riluzole persist — a scenario where continuation of the current approach must be reconsidered in light of the patient's ongoing tolerability profile.

Protocol approach (partial)

When riluzole adverse events continue without resolution, the protocol specifies a decisive course of action concerning riluzole itself. The full decision pathway — including supporting criteria and further management — is available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ene.16264

If adverse events still persist, consider stopping riluzole.

View source ↗